Jacqueline M. Matthews

Jacqueline M. Matthews

Auto-generated profile, based on publicly available information

Jacqueline M. Matthews

School of Life and Environmental Sciences, University of Sydney, NSW 2006, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
NMNeelan J. Marianayagam
Neelan J. Marianayagam
MSMargaret Sunde
Margaret Sunde
JMJacqueline M. Matthews
Jacqueline M. Matthews

1 August 2005 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
DRD Ryan
D Ryan
JMJ Matthews
J Matthews

1 May 1997 in Protein Science
Verified
Journal Article
Open access
PDF file
RSRichard J. Simpson
Richard J. Simpson
AHAnnet Hammacher
Annet Hammacher
DSDavid K. Smith
David K. Smith
JMJacqueline M. Matthews
Jacqueline M. Matthews
LWLarry D. Ward
Larry D. Ward
Interleukin‐6 (IL‐6) is a multifunctional cytokine that plays a central role in host defense due to its wide range of immune and hematopoietic activities and its potent ability to induce the acute phase response. Overexpression of IL‐6 has been implicated in the pathology of a number of diseases including multiple myeloma, rheumatoid arthritis, Castleman's disease, psoriasis, and post‐menopausal osteoporosis. Hence, selective antagonists of IL‐6 action may offer therapeutic benefits. IL‐6 is a member of the family of cytokines that includes interleukin‐11, leukemia inhibitory factor, oncostatin M, cardiotrophin‐1, and ciliary neurotrophic factor. Like the other members of this family, IL‐6 induces growth or differentiation via a receptor‐system that involves a specific receptor and the use of a shared signaling subunit, gp130. Identification of the regions of IL‐6 that are involved in the interactions with the IL‐6 receptor and gp130 is an important first step in the rational manipulation of the effects of this cytokine for therapeutic benefit. In this review, we focus on the sites on IL‐6 which interact with its low‐affinity specific receptor, the IL‐6 receptor, and the high‐affinity converter gp130. A tentative model for the IL‐6 hexameric receptor ligand complex is presented and discussed with respect to the mechanism of action of the other members of the IL‐6 family of cytokines.

1 December 2002 in IUBMB Life
Verified
Journal Article
Open access
PDF file
JMJacqueline M. Matthews
Jacqueline M. Matthews
MSMargaret Sunde
Margaret Sunde
Zinc finger domains (ZnFs) are common, relatively small protein motifs that fold around one or more zinc ions. In addition to their role as a DNA‐binding module, ZnFs have recently been shown to mediate protein:protein and protein:lipid interactions. This small zinc‐ligating domain, often found in clusters containing fingers with different binding specificities, can facilitate multiple, often independent intermolecular interactions between nucleic acids and proteins. Classical ZnFs, typified by TFIIIA, ligate zinc via pairs of cysteine and histidine residues but there are at least 14 different classes of Zn fingers, which differ in the nature and arrangement of their zinc‐binding residues. Some GATA‐type ZnFs can bind to both DNA and a variety of other proteins. Thus proteins with multiple GATA‐type fingers can play a complex role in regulating transcription through the interplay of these different binding selectivities and affinities. Other ZnFs have more specific functions, such as DNA‐binding ZnFs in the nuclear hormone receptor proteins and small‐molecule‐binding ZnFs in protein kinase C. Some classes of ZnFs appear to act exclusively in protein‐only interactions. These include the RING family of ZnFs that are involved in ubiquitination processes and in the assembly of large protein complexes, LIM, TAZ, and PHD domains. We review the similarities and differences in structure and functions of different ZnF classes and highlight the versatility of this fold.

28 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AKA. H. Y. Kwan
A. H. Y. Kwan
RWR. D. Winefield
R. D. Winefield
MSMargaret Sunde
Margaret Sunde
JMJ. M. Matthews
J. M. Matthews
RHRichard G. Haverkamp
Richard G. Haverkamp
JMJ. P. Mackay
J. P. Mackay
Class I hydrophobins are a unique family of fungal proteins that form a polymeric, water-repellent monolayer on the surface of structures such as spores and fruiting bodies. Similar monolayers are being discovered on an increasing range of important microorganisms. Hydrophobin monolayers are amphipathic and particularly robust, and they reverse the wettability of the surface on which they are formed. There are also significant similarities between these polymers and amyloid-like fibrils. However, structural information on these proteins and the rodlets they form has been elusive. Here, we describe the three-dimensional structure of the monomeric form of the class I hydrophobin EAS. EAS forms a β-barrel structure punctuated by several disordered regions and displays a complete segregation of charged and hydrophobic residues on its surface. This structure is consistent with its ability to form an amphipathic polymer. By using this structure, together with data from mutagenesis and previous biophysical studies, we have been able to propose a model for the polymeric rodlet structure adopted by these proteins. X-ray fiber diffraction data from EAS rodlets are consistent with our model. Our data provide molecular insight into the nature of hydrophobin rodlet films and extend our understanding of the fibrillar β-structures that continue to be discovered in the protein world.

27 July 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JKJan Kazenwadel
Jan Kazenwadel
KBKelly L. Betterman
Kelly L. Betterman
CCChan-Eng Chong
Chan-Eng Chong
PSPhilippa H. Stokes
Philippa H. Stokes
YLYoung K. Lee
Young K. Lee
NHNatasha L. Harvey
Natasha L. Harvey
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been shown to underlie a range of clinical phenotypes, including Emberger syndrome, a disorder characterized by lymphedema and predisposition to myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). Despite well-defined roles in hematopoiesis, the functions of GATA2 in the lymphatic vasculature and the mechanisms by which GATA2 mutations result in lymphedema have not been characterized. Here, we have provided a molecular explanation for lymphedema predisposition in a subset of patients with germline GATA2 mutations. Specifically, we demonstrated that Emberger-associated GATA2 missense mutations result in complete loss of GATA2 function, with respect to the capacity to regulate the transcription of genes that are important for lymphatic vessel valve development. We identified a putative enhancer element upstream of the key lymphatic transcriptional regulator PROX1 that is bound by GATA2, and the transcription factors FOXC2 and NFATC1. Emberger GATA2 missense mutants had a profoundly reduced capacity to bind this element. Conditional Gata2 deletion in mice revealed that GATA2 is required for both development and maintenance of lymphovenous and lymphatic vessel valves. Together, our data unveil essential roles for GATA2 in the lymphatic vasculature and explain why a select catalogue of human GATA2 mutations results in lymphedema.